Paper Details

  1. Home
  2. Paper Details

[Secukinumab-induced subacute-cutaneous lupus erythematosus].

Author: KörberA, SondermannW, WehrmannC

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This case report describes a 52-year-old woman who developed drug-induced lupus erythematosus (DILE) after starting therapy with secukinumab. The DILE improved with topical steroid therapy, and the biological agent was switched to ustekinumab.
Paper Details　
Original Abstract of the Article :
We report about a 52-year-old woman with onset of drug-induced lupus erythematosus (DILE) in sun-exposed areas, under therapy with secukinumab. Topical therapy with a steroid class 3 for 4 weeks showed substantial improvement. The systemic therapy was switched to ustekinumab. DILE is a rare but nota...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00105-017-4071-8

データ提供：米国国立医学図書館（NLM）

Secukinumab-Induced Subacute Cutaneous Lupus Erythematosus: A Case Study

This research delves into the realm of [pharmacology and dermatology], exploring a rare side effect of a medication. The study utilizes a [case study] approach to investigate the occurrence of [drug-induced lupus erythematosus (DILE)] in a patient undergoing treatment with [seukinumab]. The researchers discovered [significant improvement in the patient's condition after switching to ustekinumab], highlighting the importance of careful monitoring and prompt intervention in such cases.

The Significance of Switching Biological Agents

The study reveals that [DILE is a notable side effect of biologicals, affecting 0.5-1% of patients] and can arise during [IL-17 inhibition therapy]. The findings emphasize the need for [switching biological agents] when faced with DILE, demonstrating the [crucial role of personalized medicine] in optimizing patient outcomes.

Navigating the Desert of Side Effects: Insights for Patients

This case study serves as a reminder that even the most effective medications can have unexpected side effects. It highlights the importance of [open communication with healthcare providers] and [monitoring for any unusual symptoms]. Knowing the potential risks associated with medications empowers patients to [actively participate in their healthcare] and [make informed decisions about their treatment options].

Dr. Camel's Conclusion

Just like a camel navigating a vast desert, doctors need to be aware of the potential side effects of medications, especially those that have a unique impact on the immune system. This study serves as a beacon in the desert of pharmaceutical research, guiding physicians toward the best treatment options for their patients.
Date :
  1. Date Completed 2019-04-01
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

29075868

DOI: Digital Object Identifier

10.1007/s00105-017-4071-8

Related Literature

Article Analysis
・Side Effects of secukinumab injection
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.